Data from the second human treated with a prime edited medicine: a 56-year-old male with chronic granulotamous disease (CGD) had his bone marrow prime edited to insert the missing GT in NCF1, restoring NADPH oxidase function in neutrophils (DHR positivity) several fold beyond the

A wonderful article by Dhruv Khullar on patients with progeria, the genetics behind this rare disease, and our ongoing efforts with PRF and NIH to advance promising base editing outcomes in humanized progeria mice into a clinical trial. newyorker.com/magazine/2025/…